GET DAILY SIGNALSNeumora Therapeutics (NMRA): Path to the $6.30 Analyst Target After Major Pipeline Changes
Key Takeaways
- The central stock price target examined here is $6.30, the arithmetic mean of six verified analyst price targets, rounded from a calculated average of approximately $6.33.
- At a recent price near $0.50, reaching $6.30 would require upside of roughly 1,160%—an exceptionally large move.
- The verified analyst target range is unusually wide, from a low of $3 to a high of $14, reflecting genuine disagreement about the value of the remaining pipeline.
- The strongest supporting factor is the company's early-stage neuroscience pipeline and its roughly $117 million cash position after a workforce reduction.
- The biggest risks are the failed lead program, binary clinical-trial outcomes, a negative P/E profile, and the possibility of dilution.
- You can review Major News, Today's Price Move, Forecast, and Earnings for additional context on this ticker.
- Explore Trending AI Robots to see how AI-driven tools scan for changing market conditions across thousands of securities.
Analyst Price Targets and Consensus View
The central target is based on six individual analyst price targets that can be attributed to a specific firm and date. The most recent verified figures include H.C. Wainwright at $7 (August 2026), Needham at $5 and RBC Capital at $5 (August 2026), Mizuho at $4 (August 2026), and Stifel at $3 and Guggenheim at $14 (both from mid-2026). That produces a low-to-high range of $3 to $14 and a calculated mean of roughly $6.33, rounded to $6.30 for this article. I also checked this using Tickeron’s AI Screener to see how NMRA compares to others in the industry.
Views are far from uniform. Guggenheim's $14 reflects an optimistic valuation of the remaining early-stage assets, while Stifel's $3 and J.P. Morgan's "Sell" stance signal caution. William Blair upgraded the shares to Outperform in February 2026 without publishing a numeric target. The wide dispersion is typical of a clinical-stage biotech where the range of outcomes is driven by binary trial results rather than near-term earnings.
Current Market Position and Path Toward the Target
NMRA closed near $0.50 on November 2, 2026, down from a 52-week high of $3.65 and within a 52-week range of about $0.32 to $3.65. Reaching $6.30 would require an increase of roughly 1,160%, a very large move that would mean retracing all of the post-failure decline and then some.
Any such path would likely depend on positive data from the remaining pipeline. Following the KOASTAL-2 and KOASTAL-3 Phase 3 failures, the company discontinued navacaprant, its once-lead candidate for major depressive disorder, and cut about 35% of its workforce. The focus has shifted to earlier-stage programs, including NMRA-511 (Phase 1b for agitation in Alzheimer's disease), NMRA-861 and NMRA-898 (M4 muscarinic receptor positive allosteric modulators for schizophrenia), and preclinical candidates in Parkinson's disease and ALS.
What Could Support a Move Toward the Target
The most important support would be successful clinical data from the surviving pipeline, which could prompt analysts to raise targets substantially. The company's cash position—roughly $117 million as of its most recent quarter—plus cost reductions extend its runway and reduce immediate financing risk. A broader recovery in biotechnology sentiment, additional analyst target revisions, or a strategic partnership or acquisition interest in its brain-penetrant platform could also support the shares.
What Could Prevent the Target From Being Reached
The principal obstacle is execution risk in a pipeline of unproven, early-stage assets. Further clinical failures would likely trigger additional target cuts, as already occurred when the average target was reduced from roughly $9 to the mid-single digits after the navacaprant setbacks. The company generates no meaningful revenue, reports negative EPS, and a negative P/E ratio, meaning valuation rests almost entirely on future success. Dilution from future capital raises and continued selling pressure in a beaten-down stock are additional risks.
Technical Levels and Market Structure
NMRA remains in a pronounced long-term downtrend, having fallen from its $3.65 52-week high toward the $0.32 area. The recent low near $0.32 acts as a support level, while the $0.50 zone is now a near-term reference point. The former $3.65 high and the psychological $1.00 level represent resistance levels that would need to be reclaimed on any sustained recovery toward a $6.30 target.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual assumptions vary and no definitive timing should be assumed. Investors should monitor upcoming earnings reports, pipeline data readouts across the schizophrenia and Alzheimer's programs, analyst target revisions, cash runway updates, and any partnership or financing announcements.
Final Assessment
The $6.30 central target is the arithmetic mean of six verified analyst price targets spanning $3 to $14—an unusually wide range that reflects deep disagreement about the value of Neumora's remaining early-stage pipeline. From a price near $0.50, the required move is very large at roughly 1,160%, and it depends on clinical success, sustained cash runway, and a recovery in sentiment rather than near-term fundamentals. The strongest supports are the neuroscience pipeline and cost discipline; the biggest obstacles are binary trial risk, negative earnings, and potential dilution. No target is a guarantee, and investors should watch data readouts and analyst revisions closely.
Using Tickeron’s AI Daily Buy/Sell Signals in Practice
In my own research workflow, I often turn to Tickeron’s AI Daily Buy/Sell Signals to monitor names like NMRA. The tool applies artificial intelligence to scan thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on technical shifts and market conditions. For a volatile clinical-stage name, it helps surface momentum changes without requiring constant manual chart review, which I find adds useful context to the broader fundamental picture.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for NMRA turns positive, indicating new upward trend
NMRA saw its Momentum Indicator move above the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 50 similar instances where the indicator turned positive. In 47 of the 50 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NMRA's RSI Oscillator exited the oversold zone, 15 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 26 of 31 cases where NMRA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for NMRA just turned positive on October 08, 2026. Looking at past instances where NMRA's MACD turned positive, the stock continued to rise in 17 of 20 cases over the following month. The odds of a continued upward trend are 85%.
Following a +33.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where NMRA advanced for three days, in 146 of 167 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
NMRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NMRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for NMRA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.092) is normal, around the industry mean (3.104). P/E Ratio (-0.403) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. NMRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NMRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement